WANXING CUI’s Post

"In my experience, clinical trial evidence is only about 25% of the value proposition for CGTs, with real-world evidence and long-term follow-up constituting the remainder of the value proposition." I had a fascinating catch-up with Eric Faulkner recently where he shared insights from his 3 decades of working in cell and gene therapy market access, including on arguably the most successful CGT product launch to date, Zolgensma. https://lnkd.in/g3k3qzGg

With @nanostring ncounter custom gene panels researchers can have a focused study and can separate relevant from the non- relevant. A custom panel can be put together for any organism; study pathways affected by viral, bacterial infections, cancer and much more

Interested in learning how the #AdvancedTherapies industry can enhance today's manufacturing practices to establish fully automated, digitally integrated processes? ➡️ https://buff.ly/3BthKPL Daniel Gibson, Head of Collaborations at the Cell and Gene Therapy Catapult, highlights this and more in his key takeaways from Phacilitate's recent Advanced Therapies Europe event. Read the blog ☝️ #CellTherapy #GeneTherapy #ATMPs

Less than a week to go for #EUCROF24! CROs are telling us sponsor study protocols are becoming increasingly complex and sample-intensive. What we often hear: 🏨 More sites, more patients, and strict timelines... ..... Will the kits be customized for study needs? ..... Will sites have the kits in time for FPI? ..... Are the kits easy to use? What if the site makes collection errors? 🔍 More endpoints and specialized testing. It's hard to find the right labs... ..... Is there a lab near the site to process short-stability samples in<24h? ..... Can the lab develop and validate this biomarker assay on-time? ..... Can the lab do the testing according to protocol? ✈ Thousands of samples scattered across sites, labs, and with couriers... ..... Where is sample X? Is it collected? ..... Do I have sample visibility? How will I keep the sponsor informed? ..... Can I ensure sample & data integrity? 📊 Millions of data points generated - from disparate data sources... ..... When and how will data be transferred? What about ad hoc transfers? ..... Will I have a unified dataset in time for submission? ..... Is the data accurate, consistent and usable? Sounds familiar? Stop by our booth #4 if you're open to learning more about how we help CROs and sponsors generate endpoint data for their complex trials - while preventing delays and reducing costs. #clinicalresearch #clinicaltrials #clinicaloperations

come to discuss the affinity convective chromatography for cgt therapy regear chromatographt

We developed the FusionNW model, a potential clinical impact assessment of kinases in the pan-cancer fusion gene network. We suggest multiple kinases that need to pay attention to be used as the kinase fusion gene panel for diagnosis. Below are the multiple metrics of clinical assessment of the Tyrosine kinase group kinases by us. FusionNW output, MAII score, DoF score, and the number of expressed samples. https://lnkd.in/gCjCJg7P

AAV Analytics: Key Considerations When Developing a Clinical Program https://lnkd.in/e5E_bu5a Finding capable partners with the requisite expertise to optimize AAV processes is important for reducing variability and risk. Please join Andelyn for this webinar in which we will discuss key considerations for taking your AAV gene therapy from concept to commercialization with advanced analytics. 

Emmes provides full-service clinical trial support for Cell and Gene Therapy, guiding you through each phase of development. With over 40 years of experience, we offer tailored solutions that help you navigate the complexities of clinical research, from regulatory support to data management. Read our fact sheet to see how Emmes can help you advance the future of medicine together.                                                                                       #CRO #ClinicalDevelopment #CellAndGeneTherapy #ClinicalTrials #Emmes

Helping to better classify subgroups of patients at the molecular level both in a fast and reliable way is what nCounter does best! 👉 https://bit.ly/3OxMzGI See how researchers from The Hospital for Sick Children developed a rapid, cost-effective, and accurate subgrouping assay for atypical teratoid rhabdoid tumor using an nCounter custom gene panel. #geneexpression #classifier #cancerresearch

Regenerative medicine is not a distant reality—it's a transformative force that's shaping the world of medicinal therapeutics today. At Two Labs, we’ve proudly guided manufacturers from the earliest stages of pre-clinical development through to the life-changing patient outcomes that follow. If you missed our latest insights on the current state of the cell and gene therapy pipeline, we've made it easy to catch up. Check out our comprehensive webinar recap that charts the progress and previews the breakthroughs on the horizon. Start with the blog here and access the full webinar within for a full recap of where the pipeline stands. https://bit.ly/48wftyD